InvestorsHub Logo
Followers 38
Posts 2912
Boards Moderated 0
Alias Born 06/05/2012

Re: IrishGuy256 post# 383499

Thursday, 11/11/2021 9:48:49 PM

Thursday, November 11, 2021 9:48:49 PM

Post# of 402939
To add some more of that “perspective?.. I was afraid from the start that the patients in the “moderate to severe” category might be too far into the disease process to take optimal advantage of Brilacidin’s anti-viral capabilities. But I felt that I had to trust that all the brains involved had reason to select the moderate to severe category. Now, given the results of this trial, I am even less optimistic about those compassionate use cases. However, the mild to moderate cases should be in Brilacidin’s sweet spot. The two new drugs are both given orally (pills) but they both apparently have limited effectiveness as well as the potential for serious side effects. If Brilacidin excels in mild to moderate, it will still be the safest drug capable of making a difference for patients suffering from Covid-19 and possibly many other viruses.

Based on this and the many other irons IPIX has in the fire, I added almost 10% to my holdings today.

Irish said and I agree,

I think some perspective is required today. Brilacidin was never about Covid.


"It is difficult to get a man to understand something, when his salary depends upon his not understanding it."

Upton Sinclair

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News